◎ Sugi Atlas

Atlas / Drug / Dexmedetomidine

Dexmedetomidine

drug
On this page

Also known as DexmedetomidinaMedetomidine, (s)-MPV-1440SID11114268Dexmeditomidine

Summary

Dexmedetomidine (CHEMBL778) is an approved small-molecule α-adrenergic agonist (ATC N05CM18) targeting ADRA2A, ADRA2B, and ADRA2C; indicated across 70 conditions including obstructive sleep apnea syndrome and toxic shock syndrome.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: N05CM18
  • Targets: 3 (ADRA2A, ADRA2B, ADRA2C)
  • Indications: 70 conditions
  • Clinical trials: 1,393
  • Chemistry: 200.28 Da · C13H16N2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL778
NameDexmedetomidine
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID5311068
ChEBICHEBI:4466
ATCN05CM18
Molecular formulaC13H16N2
Molecular weight200.28
InChIKeyCUHVIMMYOGQXCV-NSHDSACASA-N

SMILES: CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C

IUPAC name: 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole

Pharmacological roles (ChEBI): α-adrenergic agonist, non-narcotic analgesic, analgesic, sedative.

Also known as: Dexmedetomidina, Dexmedetomidine, Medetomidine, (s)-, MPV-1440, SID11114268, dexmedetomidine, DEXMEDETOMIDINE, Dexmeditomidine

Parent form; salt/anhydrous children: CHEMBL2106195

Patent coverage: 3,996 distinct patent families (13,886 SureChEMBL compound mentions), from 3 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
ADRA2Aα2A-adrenoceptorAgonist7.60.1%P08913
ADRA2Bα2B-adrenoceptorFull agonist10.90.2%P18089
ADRA2Cα2C-adrenoceptorAgonist9.20%P18825

Broader ChEMBL bioactivity targets: 17 (assay-derived). Sample: Alpha-2A adrenergic receptor, Adrenergic receptor alpha-1, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Thyrotropin receptor, Adrenergic receptor alpha-2, Alpha-1D adrenergic receptor, Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Cytochrome P450 2D6.

Bioactivity

ChEMBL activities: 31 potent at pChembl ≥ 5 of 36 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
P2290910.82Ki0.01nMCHEMBL_ACT_1024074
ADRA1D10.82Ki0.01nMCHEMBL_ACT_1146518
P2290910.82Ki0.01nMCHEMBL_ACT_204005
P1932810.82Ki0.01nMCHEMBL_ACT_784949
ADRA2C9.32EC500.48nMCHEMBL_ACT_16896936
ADRA2A9.1EC500.8nMCHEMBL_ACT_16896926
ADRA2A8.82EC501.5nMCHEMBL_ACT_5130912
ADRA2B8.72EC501.91nMCHEMBL_ACT_25844440
ADRA2A8.67EC502.14nMCHEMBL_ACT_16610374
ADRA2A8.62EC502.37nMCHEMBL_ACT_25844407
ADRA2A8.6Ki2.5nMCHEMBL_ACT_16610357
ADRA2A8.5EC503.16nMCHEMBL_ACT_25844402
ADRA2B8.48EC503.31nMCHEMBL_ACT_25844403
P229098.3Ki5nMCHEMBL_ACT_1024075
P158238.3Ki5nMCHEMBL_ACT_204006
ADRA2C8.27EC505.37nMCHEMBL_ACT_25844447
ADRA1A7.88EC5013.03nMCHEMBL_ACT_25844454
ADRA2C7.54EC5028.84nMCHEMBL_ACT_25844404
ADRA2C7.51Ki30.9nMCHEMBL_ACT_1918098
CYP3A46.8Potency158.5nMCHEMBL_ACT_4981594
CYP3A46.8Potency158.5nMCHEMBL_ACT_5050621
CYP3A46.8AC50158.5nMCHEMBL_ACT_6022673
CYP1A26.8AC50158.5nMCHEMBL_ACT_6025046
CYP2C96.7Potency199.5nMCHEMBL_ACT_5057562
CYP2C96.7AC50199.5nMCHEMBL_ACT_5998973
P181306.42EC50376nMCHEMBL_ACT_16896946
ADRA1D5.91Ki1230nMCHEMBL_ACT_25844400
ADRA1A5.88Ki1318nMCHEMBL_ACT_25844386
CYP2C195.3Potency5012nMCHEMBL_ACT_4021239
CYP2C195.3AC505012nMCHEMBL_ACT_6021752

Target pathways

Aggregated over 3 target gene(s): ADRA2A, ADRA2B, ADRA2C.

Top Reactome pathways

19 total, by targets touching each:

PathwayTargetsGenes
Hemostasis3ADRA2A, ADRA2B, ADRA2C
Signal Transduction3ADRA2A, ADRA2B, ADRA2C
Signaling by GPCR3ADRA2A, ADRA2B, ADRA2C
Class A/1 (Rhodopsin-like receptors)3ADRA2A, ADRA2B, ADRA2C
Amine ligand-binding receptors3ADRA2A, ADRA2B, ADRA2C
GPCR downstream signalling3ADRA2A, ADRA2B, ADRA2C
Adrenoceptors3ADRA2A, ADRA2B, ADRA2C
Adrenaline signalling through Alpha-2 adrenergic receptor3ADRA2A, ADRA2B, ADRA2C
G alpha (i) signalling events3ADRA2A, ADRA2B, ADRA2C
G alpha (z) signalling events3ADRA2A, ADRA2B, ADRA2C
GPCR ligand binding3ADRA2A, ADRA2B, ADRA2C
Platelet activation, signaling and aggregation3ADRA2A, ADRA2B, ADRA2C
Platelet Aggregation (Plug Formation)3ADRA2A, ADRA2B, ADRA2C
Metabolism2ADRA2A, ADRA2C
Integration of energy metabolism2ADRA2A, ADRA2C
Metabolism of proteins2ADRA2A, ADRA2C
Adrenaline,noradrenaline inhibits insulin secretion2ADRA2A, ADRA2C
Regulation of insulin secretion2ADRA2A, ADRA2C
Surfactant metabolism2ADRA2A, ADRA2C

Dominant GO biological processes

GO termTargets
epidermal growth factor receptor signaling pathway3
G protein-coupled receptor signaling pathway3
negative regulation of norepinephrine secretion3
regulation of vasoconstriction3
platelet activation3
negative regulation of epinephrine secretion3
positive regulation of MAPK cascade3
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction3
adrenergic receptor signaling pathway3
adenylate cyclase-inhibiting adrenergic receptor signaling pathway3
regulation of smooth muscle contraction3
signal transduction3
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway2
female pregnancy2
negative regulation of insulin secretion2

Indications & clinical

Indications

70 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
obstructive sleep apnea syndrome3MONDO:0007147EFO:0003918
toxic shock syndrome3MONDO:0001881EFO:0006834
hypertensive disorder3MONDO:0005044EFO:0000537
subarachnoid hemorrhage3MONDO:0005099EFO:0000713
obesity disorder3MONDO:0011122EFO:0001073
injury3MONDO:0021178EFO:0000546
anxiety3MONDO:0011918EFO:0005230
cleft palate3MONDO:0016064HP:0000175
insomnia3MONDO:0013600EFO:0004698
bone fracture3MONDO:0005315EFO:0003931
opiate dependence3MONDO:0005530EFO:0005611
brain disorder3MONDO:0005560EFO:0005774
delirium3MONDO:0045057EFO:0009267
respiratory failure3MONDO:0021113EFO:0009686
gastric neoplasm3MONDO:0021085MONDO:0001056
breast neoplasm3MONDO:0021100MONDO:0007254
brain injury3MONDO:0043510MONDO:0043510
morbid obesity3MONDO:0005139EFO:0001074
pharyngitis3MONDO:0002258MONDO:0002258
neoplasm3MONDO:0005070MONDO:0004992
atrial septal defect3MONDO:0006664MONDO:0007172
rectal disorder3MONDO:0001593EFO:0000405
lung disorder3MONDO:0005275EFO:0003818
retinopathy of prematurity3MONDO:0006952EFO:1001158
colorectal neoplasm3MONDO:0005335MONDO:0005575
congenital heart disease2MONDO:0005453EFO:0005207
acute kidney injury2MONDO:0002492HP:0001919
brain neoplasm2MONDO:0021211EFO:0003833
preeclampsia2MONDO:0005081EFO:0000668
autism spectrum disorder2MONDO:0005258EFO:0003756
mental disorder2MONDO:0005084EFO:0000677
burn2MONDO:0043519EFO:0009516
adrenal gland pheochromocytoma2MONDO:0004974EFO:0000239
pulmonary hypertension2MONDO:0005149MONDO:0005149
coronary artery disorder2MONDO:0005010EFO:0001645
temporomandibular joint disorder2MONDO:0005473EFO:0005279
amyotrophic lateral sclerosis2MONDO:0004976MONDO:0004976
Riley-Day syndrome2MONDO:0009131Orphanet:1764
heart disorder1MONDO:0005267EFO:0003777
scoliosis1MONDO:0005392EFO:0004273
epilepsy1MONDO:0005027EFO:0000474
cocaine dependence1MONDO:0005186EFO:0002610
kidney failure1MONDO:0001106EFO:1002048
atrial fibrillation1MONDO:0004981EFO:0000275
Alzheimer disease1MONDO:0004975MONDO:0004975
hypotensive disorder1MONDO:0005468EFO:0005251
nasal cavity polyp1MONDO:0006314EFO:1000391
tethered spinal cord syndrome1MONDO:0006995EFO:1001210
radius fracture0MONDO:0005325EFO:0003957
vascular disorder0MONDO:0005385EFO:0004264
brain ischemia0MONDO:0005299MONDO:0005299
neuralgia0MONDO:0021667EFO:0005762
nicotine dependence0MONDO:0008575EFO:0003768

17 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1,393.

Phase distribution

PhaseTrials
Not specified510
PHASE4471
PHASE3137
PHASE289
PHASE2/PHASE373
PHASE152
EARLY_PHASE137
PHASE1/PHASE224

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03384563PHASE4RECRUITINGEffect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
NCT03480061PHASE4ACTIVE_NOT_RECRUITINGDexmedetomidine to Reduce the Incidence of POCD After Open Cardiac Surgery
NCT04289142PHASE4RECRUITINGCognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
NCT04669457PHASE4ENROLLING_BY_INVITATIONPediatric Delirium
NCT04730609PHASE4RECRUITINGDexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery
NCT05031026PHASE4ACTIVE_NOT_RECRUITINGDexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation
NCT05466708PHASE4RECRUITINGSafety and Efficacy of Esketamine Combined With Dexmedetomidine for Sedation of Mechanically Ventilated Patients
NCT05640453PHASE4RECRUITINGPregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting
NCT05934669PHASE4RECRUITINGIN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED
NCT05935293PHASE4NOT_YET_RECRUITINGDexmedetomidine and Kidney Transplantation
NCT05950646PHASE4RECRUITINGMini-dose Dexmedetomidine-Esketamine Infusion and Perioperative Sleep Quality
NCT06067893PHASE4ENROLLING_BY_INVITATIONLow Dose Dexmedetomidine as a Postoperative Pain Adjunct
NCT06139692PHASE4RECRUITINGComparison of Perioperative Conscious Sedation During Endovascular Thrombectomy in Acute Ischemic Stroke
NCT06251375PHASE4NOT_YET_RECRUITINGEarly Sedation With Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients
NCT06252662PHASE4RECRUITINGLiposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
NCT06399185PHASE4RECRUITINGEffect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort
NCT06410365PHASE4NOT_YET_RECRUITINGImpact of Intrathecal vs Intravenous Dexmedetomidine
NCT06418308PHASE4RECRUITINGIntrathecal Dexmedetomidine vs Epinephrine
NCT06480539PHASE4RECRUITINGThe Effect of Nocturnal Dexmedetomidine on Postoperative Sleep Quality and Fatigue After Major Surgery in Elderly Patients: DEXSLEEP Study
NCT06570187PHASE4RECRUITINGThe Effect of Dexmedetomidine on the Renal Functions in Septic Critically Ill Patients
NCT06575179PHASE4RECRUITINGDexmedetomidine Reduces Sevoflurane MAC-BAR During Pneumoperitoneum
NCT06631534PHASE4RECRUITINGEffect of Dexmedetomidine Supplementation to General Anaesthesia in Paediatric Transcatheter Closure of Atrial Septal Defect
NCT06636578PHASE4RECRUITINGDexmedetomidine Ropivacaine Versus Plain Ropivacaine in Bilateral Pectoralis Nerve (PECS) Block
NCT06690021PHASE4NOT_YET_RECRUITINGComparing The Effect of Adding Dexmedetomidine to Bupivacaine in Classical and Modified Thoracolumbar Interfascial Plane Block on Postoperative Pain in Patients Undergoing Lumbar Disc Surgeries
NCT06695468PHASE4NOT_YET_RECRUITINGEfficacy and Safety of Adding Dexmedetomidine to Levobupivacaine in Rectus Sheath Block Compared to Quadratus Lumborum Block in Patients Undergoing Lower Abdominal Cancer Surgery: A Randomized Clinical Trial
NCT06720337PHASE4NOT_YET_RECRUITINGComparative Study Between the Analgesic Effect of Dexmedetomidine and Magnesium Sulfate as Adjuvant to Bupivacaine Using Ultrasound-Guided Transversus Abdominis Plane Block in Abdominal Hysterectomy : A Randomized Double-blinded Study
NCT06734195PHASE4NOT_YET_RECRUITINGComparing the Synergistic Effect of Caudal Dexmedetomidine and Propofol Versus Caudal Dexmedetomidine Only or Propofol Only in Prevention of Sevoflurane Related Emergence Agitation in Pediatric Patients Undergoing Congenital Inguinal Hernia Repair
NCT06736496PHASE4NOT_YET_RECRUITINGComparative Study of Opioid-Free Anesthesia Versus Opioid Anesthesia in Patients Undergoing Laparoscopic Cholecystectomy
NCT06752317PHASE4NOT_YET_RECRUITINGEffect of Preoperative Intrathecal Dexamethasone Versus Dexmedetomidine on Paralytic Ileus After Major Abdominal Surgery
NCT06752629PHASE4NOT_YET_RECRUITINGComparison Between Dexmedetomidine and Fentanyl As an Adjuvant to Bupivacaine in the Paravertebral Nerve Block in Laparoscopic Cholecystectomy for Postoperative Analgesia: Randomized Comparative Clinical Trial.
NCT06822088PHASE4NOT_YET_RECRUITINGEffects of Esketamine on Oxygenation and Quality of Recovery in Patients Undergoing Thoracoscopic Surgery
NCT06823349PHASE4RECRUITINGComparative Analysis of Analgesic Efficacy: by Single Shot Intrathecal Analgesia (SSSA) in Normal Labor
NCT06837818PHASE4NOT_YET_RECRUITINGTo Explore the Optimal Dose of Dexmedetomidine for Skull Pin Fixation in Intracranial Surgery
NCT06849466PHASE4ENROLLING_BY_INVITATIONEffect of Perioperative Dexmedetomidine on Chronic Post-Surgical Pain
NCT06853431PHASE4RECRUITINGDetermination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoperative Sedation in Pediatric General Anesthesia
NCT06958393PHASE4NOT_YET_RECRUITINGEffect of Opioid-free Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery
NCT06981949PHASE4NOT_YET_RECRUITINGAddition of Dexmedetomidine to Ropivacaine in Bilateral Erector Spinae Plane Block in Patients Undergoing Coronary Artery Bypass Surgery
NCT07022821PHASE4RECRUITINGComparison of Dexmedetomidine + Ketamine for Postoperative Pain in C-Section
NCT07034300PHASE4RECRUITINGLidocaine vs. Lidocaine With Dexmedetomidine for Intravenous Regional Anesthesia (IVRA) in Upper Limb Surgery
NCT07034898PHASE4ENROLLING_BY_INVITATIONDexmedetomidine vs Labetalol for Airway Stress in Hypertensive Craniotomy Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

607 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
ACLIDINIUM BROMIDEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
AfatinibChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
AlmotriptanChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CHENODIOLChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CLOZAPINEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
DESLORATADINEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
DIHYDROERGOTAMINEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
GENTIAN VIOLETChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
NAPHAZOLINEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
OLANZAPINEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
OLODATEROLChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
PALIPERIDONEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
PRAMIPEXOLEChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
TAMSULOSINChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
TEGASERODChEMBL + PubChemPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
ACETOPHENAZINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
ALFUZOSINChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
AMISULPRIDEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
AMITRIPTYLINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
AMOXAPINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
APOMORPHINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
APRACLONIDINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
ARIPIPRAZOLEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
ASENAPINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
ASTEMIZOLEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
AZELASTINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
BAZEDOXIFENEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
BENFLUOREXChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
BENPERIDOLChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
BENZBROMARONEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
BENZQUINAMIDEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
BENZTHIAZIDEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
BENZTROPINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
BITHIONOLChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
BREXPIPRAZOLEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
BRIMONIDINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
BROMOCRIPTINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
BROMPERIDOLChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CABERGOLINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CARIPRAZINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CARVEDILOLChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CHLORHEXIDINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CHLOROQUINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CHLORPROMAZINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CINNARIZINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CISAPRIDEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CLEMASTINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CLOMIPRAMINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CLONIDINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CLOTRIMAZOLEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
CYPROHEPTADINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
DANAZOLChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
DARIFENACINChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
DOBUTAMINEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
DOMPERIDONEChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
DOTHIEPINChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C
DOXAZOSINChEMBLPhase 4 (approved)ADRA2A, ADRA2B, ADRA2C

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot